The National Institute for Health and Care Excellence (NICE) has recommended sofosbuvir–velpatasvir–voxilaprevir (Vosevi) as a treatment option for chronic hepatitis C in adults.
Sofosbuvir–velpatasvir–voxilaprevir is recommended for treatment of adults with chronic hepatitis C as specified below:
- 12-week regimen for individuals infected with HCV genotype 1-6 with or without compensated cirrhosis who have previously been treated with direct-acting antivirals (DAAs).
- 8-week regimen for individuals infected with HCV genotype 3 with or without compensated cirrhosis who have not previously received treatment with DAAs.
Clinical evidence has shown sofosbuvir–velpatasvir–voxilaprevir to be effective against all HCV genotypes, regardless of the individual’s cirrhosis status and treatment history. The recommended dose for sofosbuvir–velpatasvir–voxilaprevir is 1 tablet (400 mg/100mg/100mg) once-daily taken orally for 8-12 weeks.
The therapy is to be used only when it is provided by the company at the same price or lower than that agreed with the Commercial Medicines Unit. The recommendations should not affect patients whose treatment with the medication was started before publication of the guidance.
